Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rockwell Medical (RMTI) Non-Current Deffered Revenue (2016 - 2024)

Rockwell Medical (RMTI) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $429000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Non-Current Deffered Revenue fell 9.68% year-over-year to $429000.0, compared with a TTM value of $429000.0 through Dec 2024, down 9.68%, and an annual FY2024 reading of $429000.0, down 9.68% over the prior year.
  • Non-Current Deffered Revenue was $429000.0 for Q4 2024 at Rockwell Medical, down from $441000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $9.5 million in Q1 2020 and bottomed at $429000.0 in Q4 2024.
  • Average Non-Current Deffered Revenue over 5 years is $4.4 million, with a median of $4.8 million recorded in 2022.
  • The sharpest move saw Non-Current Deffered Revenue tumbled 89.33% in 2023, then dropped 9.45% in 2024.
  • Year by year, Non-Current Deffered Revenue stood at $8.0 million in 2020, then fell by 25.32% to $6.0 million in 2021, then plummeted by 56.57% to $2.6 million in 2022, then crashed by 81.73% to $475000.0 in 2023, then decreased by 9.68% to $429000.0 in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for RMTI at $429000.0 in Q4 2024, $441000.0 in Q3 2024, and $452000.0 in Q2 2024.